Abstract: A method for preparing a trained complete selective classifier can be applied to a trained complete selective classifier having an existing trained selection mechanism. The trained selective classifier is modified to disregard the existing trained selection mechanism and use, as a basis for an alternate selection mechanism, at least one classification prediction value, for example the predictive entropy or the maximum predictive class logit. Optionally, before modifying the trained selective classifier, the method commences with an untrained selective classifier, which may be trained with a modified loss function to obtain the trained selective classifier. The modified loss function has at least one added term, relative to an original loss function, and the at least one added term decreases entropy.

Abstract: A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.

Abstract: A computer-implemented system and method for training a neural network with enforced monotonicity are disclosed. An example system includes at least one processor and memory in communication with said at least one processor, wherein the memory stores instructions for providing a data model representing a neural network for predicting an outcome based on input data, the instructions when executed at said at least one processor causes said system to: receive a feature data as input data; predict an outcome based on the input data using the neural network; compute a loss function based on the predicted outcome and an expected outcome associated with the input data, the loss function being dependent on a monotonicity penalty ? computed based on a set of training data including the feature data and on a set of random data; and update weights of the neural network based on the loss function.

Abstract: A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.

Abstract: Thioctamer, a nanoconjugate of glatiramer acetate (GA) and thioctic acid (TA), e.g. in the form of nanospheres, is provided as are compositions comprising thioctamer and methods of using the same for wound healing. Application of thioctamer to a wound accelerates wound healing, compared to control wounds that are not treated with the copolymer.

Abstract: Nanoparticulate, ion-paired complexes of melittin (MLN) and one or more non-steroidal anti-inflammatory drugs, and particularly MLN ion-paired with diclofenac, provide for enhanced wound healing in humans and other animals. Compositions having the nanonparticulates distributed therein or thereon are applied topically to the wound, and the ion-paired complexes have been shown to demonstrate superior wound healing and closure.

Abstract: A transdermal film formulation containing transfersomes incorporated onto the transdermal film is provided. The transfersomes include avanafil, a phospholipid, and an edge activator, wherein the phospholipid to avanafil ratio is from 3.5:1 to 4.5:1 and wherein the edge activator has a hydrophilic-lipophilic (HLB) value of 2-4. Methods of making the transdermal film formulation and methods of delivering avanafil using the transdermal film formulation are also provided.

Abstract: A rotatory resectoscope is disclosed with a novel mechanism for endoscopic resection. Resection is performed by a rotary motion instead of the conventional linear motion. A novel resection loop and working element for controlling the movement of the resection loop allow the resection loop to move in clockwise and counterclockwise rotation. Embodiments include both monopolar and bipolar diathermy resectoscopes.

Abstract: Micelle formulations comprising a tocopherol or derivative thereof, alpha lipoic acid, and a biologically active agent such as vinpocetine are provided. Films for transdermal delivery containing the micelle formulation and methods of treating cognitive and cerebrovascular disorders are also provided.

Abstract: A drug product comprising: a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy} hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11ß,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.

Abstract: Nanosized avanafil (AVA) invasomes with enhanced transdermal delivery are provided. AVA invasomes were prepared with a vesicular size of 109.92 nm and an entrapment efficiency of 96.98%. The AVA invasomal film showed enhanced ex vivo permeation bioavailability compared to a raw AVA film.

Abstract: Methods of enhancing cognition and/or memory and methods of treating cognitive and cerebrovascular disorders by intranasally administering an in situ gelling composition comprising micelles formed with tocopherol or a derivative thereof are provided. The micelles encapsulate a biological active agent such as vinpocetine. The methods provide for enhanced brain targeting of the biological active agent.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A nano-pharmaceutical formulation, comprising pumpkin seed oil; D-?-tocopheryl polyethylene glycol succinate (TPGS); and polyethylene glycol (PEG) 200 is provided. Additional cardioprotective therapies such as quercetin may be included in the formulation. Methods of treating cardiac dysfunction by administering the formulation are also provided.

Abstract: Dapoxetine nanoparticles comprising zein and alpha lipoic acid (ALA) are provided. When present in zein-ALA loaded nanoparticles, dapoxetine exhibits increased bioavailability (compared to conventional formulations) when administered to subjects for the prevention or treatment of premature ejaculation (PE). Thus, lower doses are administered, and side effects are attenuated or eliminated.

Abstract: A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhibits a Relative Humidity of from 20% to 40%.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A cranial cap dressing for dressing a craniotomy wound comprising a breathable elastic outer layer sized to fit snuggly on a human head of a patient and an absorbent inner layer attached to the breathable elastic outer layer.

Abstract: A drug product comprises a dry powder inhalation device having a pharmaceutical composition present therein, said pharmaceutical composition comprising a compound which is (6?, 11?, 16?, 17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1, 4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material, and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein, wherein the enclosed volume exhitbits a Relative Humidity of from 20% to 40%.

Abstract: A drug product comprises a dry powder inhalation device containing one or more pharmaceutical compositions present therein, wherein the one or more pharmaceutical compositions comprise active ingredients (I) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a salt thereof, and (II) (6?,11?,16?,17?)-6,9-difluoro-17-{[(fluoromethyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate or a solvate thereof; a hygroscopic material; and a package which encompasses the dry powder inhalation device and the hygroscopic material defining an enclosed volume therein; wherein each of the active ingredients (I) and (II) are present in the same or different pharmaceutical compositions, and wherein the enclosed volume within the package exhibits a Relative Humidity of from 20% to 40%.